Copyright
©The Author(s) 2016.
World J Gastroenterol. Feb 7, 2016; 22(5): 1859-1868
Published online Feb 7, 2016. doi: 10.3748/wjg.v22.i5.1859
Published online Feb 7, 2016. doi: 10.3748/wjg.v22.i5.1859
Table 1 Modality-specific staging criteria
| Stage | Criteria |
| T stage | CT criteria |
| T2/3 | Neoplasm shows focal or diffuse thickening of gastric wall with transmural involvement, is almost well enhanced, and has smooth outer wall border and clear fat plane around tumor |
| T4a | Transmural tumor with irregular or nodular outer border and/or perigastric fat infiltration |
| T4b | Obliteration of fat plane between gastric tumor and adjacent organ or invasion of adjacent organ |
| M stage | CT criteria |
| M0 | Distant metastasis absent |
| M1 | Distant metastasis present |
| T stage | EUS criteria |
| T2/3 | Tumor extent beyond the muscularis propria up to 4 mm |
| T4a | Tumor extent beyond the muscularis propria greater than 4 mm |
| T4b | Direct extension and invasion of tumor into adjacent organ |
| M stage | EUS criteria |
| M0 | Distant metastasis absent |
| M1 | Distant metastasis present |
| T stage | SL criteria |
| T2/3 | Tumor with clear and smooth outer gastric surface |
| T4a | Tumor with nodular or irregular outer gastric surface |
| T4b | infiltration of adjacent organs |
| M stage | SL criteria |
| M0 | Distant metastasis absent |
| M1 | Distant metastasis present |
Table 2 Agreement of computed tomographic and laparoscopic staging of T stage (n = 582)
| Computed tomography | Staging laparoscopy | |||||||||
| T2/3 | T4a | T4b | T2/3 | T4a | T4b | |||||
| Final stage | ||||||||||
| T2/3 | 115 | 35 | 3 | 126 | 27 | 0 | ||||
| T4a | 82 | 176 | 4 | 49 | 212 | 1 | ||||
| T4b | 22 | 136 | 9 | 0 | 0 | 167 | ||||
| Acc. | Sens. | Spec. | PPV | NPV | Acc. | Sens. | Spec. | PPV | NPV | |
| T2/3 | 76% | 75% | 76% | 53% | 90% | 87% | 82% | 89% | 72% | 93% |
| T4a | 56% | 67% | 47% | 51% | 63% | 87% | 81% | 92% | 89% | 85% |
| T4b | 72% | 5% | 98% | 56% | 72% | 100% | 100% | 100% | 99% | 100% |
Table 3 Agreement of endoscopic and laparoscopic staging of T stage (n = 150)
| Endoscopic ultrasound | Staging laparoscopy | |||||||||
| T2/3 | T4a | T4b | T2/3 | T4a | T4b | |||||
| Final stage | ||||||||||
| T2/3 | 28 | 42 | 3 | 64 | 9 | 0 | ||||
| T4a | 4 | 29 | 18 | 8 | 42 | 1 | ||||
| T4b | 0 | 11 | 15 | 0 | 0 | 26 | ||||
| Acc. | Sens. | Spec. | PPV | NPV | Acc. | Sens. | Spec. | PPV | NPV | |
| T2/3 | 67% | 38% | 95% | 88% | 62% | 89% | 88% | 90% | 89% | 88% |
| T4a | 50% | 57% | 46% | 35% | 68% | 88% | 82% | 91% | 82% | 91% |
| T4b | 79% | 58% | 83% | 42% | 90% | 99% | 100% | 99% | 96% | 100% |
Table 4 Agreement of computed tomographic and laparoscopic staging of M stage (n = 582)
| Computed tomography | Staging laparoscopy | ||||||||||
| M0 | M1 | M0 | M1 | ||||||||
| Final stage | M0 | 442 | 2 | 444 | 0 | ||||||
| M1 | 121 | 17 | 2 | 136 | |||||||
| Acc. | Sens. | Spec. | PPV | NPV | Acc. | Sens. | Spec. | PPV | NPV | ||
| M1 | 79% | 89% | 79% | 12% | 100% | 100% | 100% | 100% | 99% | 100% | |
Table 5 Relationship between clinicopathologic features determined by clinical staging and peritoneal metastasis or positive cytology (n = 582)
| Characteristic | P-negative(n = 457) | P-positive(n = 125) | P value |
| Gender | 0.001 | ||
| Male (n = 397) | 328 | 69 | |
| Female (n = 185) | 129 | 56 | |
| Age | 0.573 | ||
| < 65 (n = 441) | 334 | 88 | |
| ≥ 65 (n = 141) | 123 | 37 | |
| ECOG score | 0.751 | ||
| 0 (n = 224) | 175 | 49 | |
| 1 (n = 291) | 227 | 64 | |
| 2 (n = 67) | 55 | 12 | |
| Tumor size (mm) | < 0.001 | ||
| < 40 (n = 238) | 215 | 21 | |
| ≥ 40 (n = 346) | 242 | 104 | |
| Upper third | 0.903 | ||
| Not involved (n = 455) | 358 | 97 | |
| Involved (n = 127) | 99 | 28 | |
| Middle third | < 0.001 | ||
| Not involved (n = 401) | 333 | 68 | |
| Involved (n = 181) | 124 | 57 | |
| Lower third | 0.750 | ||
| Not involved (n = 200) | 159 | 41 | |
| Involved (n = 382) | 298 | 84 | |
| fT stage | < 0.001 | ||
| T2/3 (n = 153) | 145 | 8 | |
| T4a (n = 262) | 232 | 30 | |
| T4b (n = 167) | 80 | 87 | |
| Borrmann type | < 0.001 | ||
| Type I or II (n = 285) | 265 | 20 | |
| Type III (n = 253) | 166 | 87 | |
| Type IV (n = 44) | 26 | 18 | |
| Differentiation | 0.293 | ||
| Differentiated (n = 577) | 454 | 123 | |
| Undifferentiated (n = 5) | 3 | 2 | |
| Lymph node metastasis | 0.305 | ||
| Negative (n = 240) | 183 | 57 | |
| Positive (n = 342) | 274 | 68 |
Table 6 Correlation between clinicopathologic features determined by clinical staging and peritoneal metastasis or positive cytology (multivariate analysis)
| Variables | P value | Odd ratio | 95%CI |
| Tumor size (mm) | |||
| < 40 | 1.000 | ||
| ≥ 40 | 0.015 | 2.123 | 1.160-3.887 |
| fT stage | < 0.001 | ||
| T2/3 | 1.000 | ||
| T4a | 0.215 | 1.714 | 0.731-4.020 |
| T4b | < 0.001 | 11.54 | 4.942-26.947 |
| Borrmann type | < 0.001 | ||
| Type I or II | 1.000 | ||
| Type III | < 0.001 | 6.291 | 3.524-11.231 |
| Type IV | < 0.001 | 5.844 | 2.457-13.904 |
Table 7 Indications for staging laparoscopy determined based on the number of independent risk factors
| No. of independentrisk factors | P0 CY0 | P1 or CY1 | Total |
| 0, 1 | 314 | 19 | 333 |
| 2, 3 | 143 | 106 | 249 |
| Total | 457 | 125 | 582 |
| Accuracy | 72% | ||
| Sensitivity | 85% | ||
| Specificity | 69% | ||
| PPV | 43% | ||
| NPV | 94% |
- Citation: Hu YF, Deng ZW, Liu H, Mou TY, Chen T, Lu X, Wang D, Yu J, Li GX. Staging laparoscopy improves treatment decision-making for advanced gastric cancer. World J Gastroenterol 2016; 22(5): 1859-1868
- URL: https://www.wjgnet.com/1007-9327/full/v22/i5/1859.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i5.1859
